Literature DB >> 29764573

[Clinical and laboratory characteristics of juvenile myelomonocytic leukemia].

Yuan-Yuan Wu1, Sheng-Yang Cai, Wei Huang, Si-Si Li, Wei Li, Ao Dong.   

Abstract

OBJECTIVE: To study the clinical and laboratory characteristics of juvenile myelomonocytic leukemia (JMML).
METHODS: The clinical characteristics and laboratory results were retrospectively analyzed in 10 children with newly diagnosed JMML. They were compared with those of 28 children with myelodysplastic syndrome (MDS) and 44 children with chronic myeloid leukemia (CML).
RESULTS: Compared with the children with CML or MDS, the children with JMML had significantly higher rates of skin rashes, ecchymosis, and lymphadenectasis, a significantly lower serum cholinesterase (ChE) level, and a significantly higher fetal hemoglobin level (P<0.05). The white blood cell count of children with JMML was significantly higher than that of children with MDS, but significantly lower than that of children with CML (P<0.05). In addition, the myeloid/erythroid ratio and rate of dyshaematopoiesis were significantly lower in children with JMML than those in children with CML or MDS. The children with JMML had a significantly higher expression of mature monocyte marker CD14 than those with CML or MDS (P<0.05). The levels of myeloid markers CD33, CD11b, CD13, and CD15 in children with JMML were significantly higher than those in children with MDS, but significantly lower than those in children with CML (P<0.05). The levels of CD2 and CD7 in children with JMML were higher than those in children with CML, but lower than those in children with MDS (P<0.05).
CONCLUSIONS: Skin rashes, ecchymosis, lymphadenectasis, and ChE reduction are more common in children with JMML than in those with CML or MDS, while dyshaematopoiesis is less common. In addition, CD14 level increases significantly in children with JMML.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29764573      PMCID: PMC7389063     

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  17 in total

1.  Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.

Authors:  Takuya Koie; Chikara Ohyama; Hayato Yamamoto; Shingo Hatakeyama; Atsushi Imai; Takahiro Yoneyama; Yasuhiro Hashimoto; Masato Kitayam; Kazuyoshi Hirota
Journal:  Urol Oncol       Date:  2014-06-18       Impact factor: 3.498

Review 2.  Juvenile myelomonocytic leukemia.

Authors:  Prakash Satwani; Justine Kahn; Christopher C Dvorak
Journal:  Pediatr Clin North Am       Date:  2015-02       Impact factor: 3.278

3.  Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response.

Authors:  Qi Shen; Juan Ouyang; Guilin Tang; Elias J Jabbour; Guillermo Garcia-Manero; Mark Routbort; Sergej Konoplev; Carlos Bueso-Ramos; L Jeffrey Medeiros; Jeffrey L Jorgensen; Sa A Wang
Journal:  Eur J Haematol       Date:  2015-04-17       Impact factor: 2.997

4.  Butyrylcholinesterase as a marker of inflammation and liver injury in the acute and subclinical phases of canine ehrlichiosis.

Authors:  Guilherme M do Carmo; Leandro Z Crivellenti; Nathieli B Bottari; Gustavo Machado; Sofia Borin-Crivellenti; Rafael N Moresco; Thiago Duarte; Marta Duarte; Mirela Tinucci-Costa; Vera M Morsch; Maria Rosa C Schetinger; Lenita M Stefani; Aleksandro S Da Silva
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2015-10-09       Impact factor: 2.268

Review 5.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

6.  Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion.

Authors:  Shuichi Mitsunaga; Taira Kinoshita; Takahiro Hasebe; Toshio Nakagohri; Masaru Konishi; Shinichiro Takahashi; Naoto Gotohda; Atsushi Ochiai
Journal:  Pancreas       Date:  2008-04       Impact factor: 3.327

7.  Significance of serum butyrylcholinesterase levels in oral cancer.

Authors:  K Prabhu; D Naik; S Ray; A Rao; A Kamath
Journal:  Australas Med J       Date:  2011-07-31

Review 8.  Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes.

Authors:  Matteo G Della Porta; Cristina Picone
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-02-15       Impact factor: 2.576

9.  The genomic landscape of juvenile myelomonocytic leukemia.

Authors:  Elliot Stieglitz; Amaro N Taylor-Weiner; Tiffany Y Chang; Laura C Gelston; Yong-Dong Wang; Tali Mazor; Emilio Esquivel; Ariel Yu; Sara Seepo; Scott Olsen; Mara Rosenberg; Sophie L Archambeault; Ghada Abusin; Kyle Beckman; Patrick A Brown; Michael Briones; Benjamin Carcamo; Todd Cooper; Gary V Dahl; Peter D Emanuel; Mark N Fluchel; Rakesh K Goyal; Robert J Hayashi; Johann Hitzler; Christopher Hugge; Y Lucy Liu; Yoav H Messinger; Donald H Mahoney; Philip Monteleone; Eneida R Nemecek; Philip A Roehrs; Reuven J Schore; Kimo C Stine; Clifford M Takemoto; Jeffrey A Toretsky; Joseph F Costello; Adam B Olshen; Chip Stewart; Yongjin Li; Jing Ma; Robert B Gerbing; Todd A Alonzo; Gad Getz; Tanja Gruber; Todd Golub; Kimberly Stegmaier; Mignon L Loh
Journal:  Nat Genet       Date:  2015-10-12       Impact factor: 38.330

10.  Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores.

Authors:  Suiellen C Reis-Alves; Fabíola Traina; Guilherme Harada; Paula M Campos; Sara T O Saad; Konradin Metze; Irene Lorand-Metze
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.